8 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
: Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
: Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benignOther types of obesity not related
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
: Obesity due to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
to suspected POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign.Other types of obesity not related
jfk6sf 6t
RYTM
29 Apr 24
variants classified as benign or likely benignOther types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity
qm40u95ipx 7bn04jdf24xc036altqqkq2nn
RYTM
24 Apr 24
, PCSK1 or LEPR variants classified as benign or likely benign Other types of obesity not related to POMC, PCSK1 or LEPR deficiency
u2fq5adtik seiro9f1w14k2m36vlsdk8w5zxk1h35ct8
RYTM
16 Apr 24
variants classified as benign or likely benignOther types of obesity not related to POMC, PCSK1 or LEPR deficiency, or BBS, including obesity
- Prev
- 1
- Next